Applied Health Sciences - Health Sciences
Dr. Tammemagi is an epidemiologist on the US National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. In the PLCO trial Dr. Tammemagi has and is leading a number of ancillary studies and he is full active member of the PLCO Lung Committee.
Dr. Tammemagi is an epidemiologist on the US National Cancer Institute’s National Lung Screening Trial (NLST). He is full active member of the NLST Epidemiology and Health Services Research Working Group. Also, Dr. Tammemagi is Co-Chair of the NLST Joint Epidemiology Working Group, and he is leading several ancillary studies in the NLST.
Dr. Tammemagi is an epidemiologist/analyst and co-investigator in the Pan -Canadian Early Detection of Lung Cancer Study.
Dr. Tammemagi is leading a study that is evaluating the impact of computed tomography chest screening on quality of life in the following study: Low-dose computed tomography for the early diagnosis of mesothelioma and lung cancer in prior asbestos workers.
Other Recent/Current Research Activities
Dr. Tammemagi is an Associate Member of the U.S. National Institutes of Health and National Cancer Institute’s Cancer Intervention and Surveillance Modeling Network (CISNET) Lung Cancer Group. (September 2008 to present).
Dr. Tammemagi has been member of the Canadian Partnership Against Cancer Expert Panel on Lung Cancer Screening, which met on numerous occasions through 2011 and and is co-author of: Lam S, Dickinson J, Evans B, Johnston M, Mai V, Mayo J, Miller A, Morrison H, Tammemagi M, Yang H. Lung Cancer Screening – Expert Panel: Summary of Existing and New Evidence; September 22, 2011. Canadian Partnership Against Cancer.
The Canadian Partnership Against Cancer has organized the Pan-Canadian Lung Cancer Screening Network to develop a Lung Cancer Screening Framework for Canada. Dr. Tammemagi is Chairman of the Identification of High Risk Individuals Committee, one of the six core committees making up this initiative. (March 2013 to present)
Dr. Tammemagi is a lead member of the International Association for the Study of Lung Cancer (IASLC) Strategic CT Screening Advisory Committee (SSAC) High Risk Steering Group. He along with Dr. John Field drafted the 2013 annual report and he presented it at the Sydney, Australia 27 October 2013 IASLC Workshop. (June 2012 to present)
Dr. Tammemagi is an associate investigator on the Institute for Clinical Evaluative Sciences (ICES)-based study: Health Technology Assessment of Low Dose Helical CT Lung Screening for Lung Cancer(P.I. is Dr. Lawrence Paszat). This study is developing methodologies for implementation, and is piloting implementation, of population-based LDCT lung cancer screening in Ontario. (July 2013 to present)
Recent Invited Academic Presentations by Dr. Tammemagi
Tammemagi MC. Invited speaker: Lung cancer risk prediction modeling. Terry Fox Research Institute – 3rd Annual Scientific Meeting, May 11, 2012, Victoria, British Columbia.
Tammemagi MC. Invited speaker: Cancer Prediction Modeling. Brock-Kobe Universities Collaboration Workshop in Scientific Computation. May 20-22, 2012. Kobe, Japan
Tammemagi MC. Invited speaker: Who Should We Screen for Lung Cancer? In: General Session VI. Lung Cancer Screening – One Year Later – Where Are We? 2012 Multidisciplinary Symposium in Thoracic Oncology. September 6-8, 2012. Chicago.
Tammemagi MC. Invited speaker: What’s New in Risk Prediction Models for Lung Cancer? In Symposium: Risky Business: Risk and Decision Models in Lung Cancer. CHEST 2012. Atlanta, Georgia, October 20-25, 2012.
Tammemagi MC. Invited speaker: Update on Lung Cancer Screening – Where Are We Now. In Session: Early Lung Cancer Detection. Canadian Respiratory Conference. April 12, 2013. Quebec City, Quebec.
Tammemagi MC. Invited speaker: Selection Criteria for Lung Cancer Screening – Incidence versus Mortality Models. Cancer Intervention and Surveillance Modeling Network (CISNET) meeting, Ann Arbor, Michigan, 6 May 2013.
Tammemagi MC. Invited speaker: Modeling Lung Cancer Risk, In Symposium: Lung Cancer Screening: Moving Forward, and Looking Forward. American Thoracic Society (ATS) Annual Meeting. May 17-22, 2013, Philadelphia, Pennsylvania.
Tammemagi MC. Invited speaker: Lung Cancer Screening, In Symposium: High-Risk Populations and Cancer Screening. American Society for Clinical Oncology (ASCO) Annual Meeting. June 1-4, 2013, Chicago, Illinois.
Tammemagi MC. Invited speaker: Can Statistical Learning Machines Outperform Traditional Regression Models in Lung Cancer Prediction? Brock and Kobe Universities Computer Sciences Workshop. Brock University, St. Catharines, 20 August 2013.
Tammemagi MC. Chair of the High-Risk for Lung Cancer Committee presentation at the Canadian Partnership Against Cancer - Pan-Canadian Early Detection of Lung Cancer Screening Network workshop. Halifax, 2 October 2013.
Tammemagi MC, Field JK. Dr. Tammemagi led the writing of the High Risk Steering Group Report – Short and Long-term Goals and presented it at the International Association for the Study of Lung Cancer (IASLC) Strategic CT Screening Advisory Committee (SSAC) Lung Cancer CT Screening Workshop October 27, 2013, Sydney, Australia.
Tammemagi MC. Invited speaker: Risk Stratification for Lung Cancer Screening Studies. In session: Low-dose computed lung screening. At the 15th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. October 28, 2013, Sydney, Australia.
Tammemagi MC. Invited speaker: Lung cancer risk models for targeting screening. Cancer Intervention and Surveillance Modeling Network (CISNET) annual meeting. Bethesda, MD. December 5, 2013.
Tammemagi MC. Invited speaker: Screening for lung cancer. At the Canadian Lung Cancer Conference. 7 February 2014, Vancouver, BC.
Tammemagi MC. Lung cancer screening for the general population – How should occupational exposures be considered? – The risk model approach. The Occupational Cancer Research Center Lung Cancer Screening Symposium. 24 February 2014, Toronto, Ontario.
Office: Walker Complex - Academic South 306
T 905 688 5550 x5169
F 905 688 8954